First Treatment Approved for Disease Linked to Stem Cell Transplant – U.S. News & World Report
OncLive |
First Treatment Approved for Disease Linked to Stem Cell Transplant
U.S. News & World Report WEDNESDAY, March 30, 2016 (HealthDay News) — Defitelio (defibrotide sodium) has been approved by the U.S. Food and Drug Administration to treat a rare, but usually fatal liver disease that affects some people who have had a stem cell transplant. FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow |
